How to Reconstitute 60 mg Tirzepatide: A Step-by-Step Guide for Safe Mixing

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · Sources listed below

Key Takeaways

• A 60 mg tirzepatide vial requires 2 to 6 mL of bacteriostatic water depending on your target concentration; 3 mL creates a common 20 mg/mL solution
• Reconstitution must happen in a specific order: inject air first, add water slowly down the vial wall, never shake, and allow 2-3 minutes for complete dissolution
• The concentration you create determines every future dose measurement; a 60 mg vial at 20 mg/mL yields twelve 2.5 mg doses at 12.5 units each
• Discard reconstituted vials by the pharmacy's beyond-use date (commonly 28 days under USP <797>); no published stability study covers patient-reconstituted tirzepatide, so check clarity before every injection

The short answer

To reconstitute a 60 mg tirzepatide vial, inject 3 mL of bacteriostatic water slowly down the inside wall of the vial, creating a 20 mg/mL solution. Swirl gently until the powder fully dissolves (2-3 minutes). This concentration yields clean unit measurements on a U-100 insulin syringe for standard tirzepatide doses.

Status as of September 5, 2026: FDA-approved tirzepatide (Zepbound, Mounjaro) is supplied only as a ready-to-use solution; the approved multi-dose vial holds 60 mg in 2.4 mL (25 mg/mL) and is never reconstituted (Zepbound label, September 2026). Lyophilized 60 mg powder vials come either from a compounding pharmacy under a prescription or from sellers marketing them "for research use." On March 31, 2026 the FDA sent a warning letter to one such seller for marketing retatrutide, tirzepatide and bacteriostatic water as research chemicals intended for human use. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and as of May 31, 2026 it had received more than 730 adverse-event reports for compounded tirzepatide. Reconstitute only a product dispensed to you by a licensed pharmacy, following that pharmacy's instructions.

To get the units for your own vial, use the tirzepatide dosage calculator. Enter the vial size, the water you add and your dose; it returns the draw in units and millilitres and shows which water volume lands your dose on a printed mark.

Table of contents

1. Why 60 mg vials require reconstitution
2. What most articles get wrong about reconstitution volume
3. Materials checklist: everything you need before starting
4. The concentration decision: choosing your bacteriostatic water volume
5. Step-by-step reconstitution protocol
6. Post-reconstitution concentration verification
7. Dose conversion chart for 60 mg vials at every common concentration
8. The three failure modes of compounded reconstitution
9. Storage, stability, and visual inspection requirements
10. When reconstituted tirzepatide fails the safety check
11. What the approved tirzepatide vial looks like, for comparison
12. Regulatory and safety context as of September 5, 2026
13. FAQ
14. Sources

Why 60 mg vials require reconstitution

Compounding pharmacies ship tirzepatide in two formats: pre-mixed liquid vials and lyophilized (freeze-dried) powder vials. Lyophilized 60 mg vials are a compounding and research-vendor format; the FDA-approved product is supplied only as a solution, including a 60 mg per 2.4 mL multi-dose vial that the label allows at room temperature for 30 days (Zepbound label, section 16.2, September 2026). Correction, September 2026: an earlier version said high-concentration solutions are unstable in shipping; that rationale had no source and has been removed.

You reconstitute by adding bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative) to the powder. The powder dissolves, creating an injectable solution at whatever concentration you choose based on the water volume you add.

The 60 mg vial size is popular for patients on maintenance doses (10 mg to 15 mg weekly) because it provides a 4 to 6 week supply in a single vial. Smaller vials (10 mg, 30 mg) are common during titration; larger vials (100 mg) exist but require more bacteriostatic water than most patients want to inject per dose.

Reconstitution is a one-time event per vial. Once mixed, the solution stays liquid. You don't re-reconstitute before each injection.

What most articles get wrong about reconstitution volume

Some reconstitution guides online state "add 2 mL of bacteriostatic water to a 60 mg vial" without explaining that this creates a 30 mg/mL concentration, which forces fractional-unit dosing that's hard to read on a U-100 syringe. A 2.5 mg dose at 30 mg/mL is 8.3 units. A 12.5 mg dose is 41.7 units. Patients round, over-draw, or call the pharmacy confused.

The error stems from copying instructions written for 10 mg vials (where 1 mL is standard) and scaling linearly. But concentration choice isn't about matching powder-to-water ratios across vial sizes. It's about creating a final solution where your prescribed dose lands on a readable syringe marking.

For a 60 mg vial, 3 mL of bacteriostatic water creates a 20 mg/mL solution. Every common tirzepatide dose becomes a clean or half-unit measurement:

• 2.5 mg = 12.5 units
• 5 mg = 25 units
• 7.5 mg = 37.5 units
• 10 mg = 50 units
• 12.5 mg = 62.5 units
• 15 mg = 75 units

The 20 mg/mL concentration is the sweet spot for 60 mg vials. Some pharmacies pre-print instructions for 6 mL (creating 10 mg/mL), which also works but doubles injection volume. A 10 mg dose at 10 mg/mL is 100 units (1 mL), which is the entire capacity of a 1 mL insulin syringe.

Materials checklist: everything you need before starting

Gather these items before opening the tirzepatide vial:

• 60 mg tirzepatide vial (lyophilized powder). Confirm "60 mg" on the label. Vials look similar; double-check before reconstituting.
• Bacteriostatic water for injection (0.9% benzyl alcohol). You need 3 mL minimum. Most pharmacies supply a 10 mL or 30 mL vial. Do not use sterile water without preservative (shelf life drops to 24 hours after reconstitution) or saline (changes osmolarity).
• Two 3 mL syringes with needles. One draws bacteriostatic water, one injects it into the tirzepatide vial. 20-gauge to 22-gauge needles work. Insulin syringes are too small for this step.
• Alcohol swabs. Minimum of three (one per vial top, one for the work surface).
• Sharps container. For disposing of needles after reconstitution.
• Clean, flat work surface. Kitchen counter or table wiped with disinfectant. Not carpet, not bathroom.
• Good lighting. You need to see the powder dissolve completely.
• Timer or clock. To track the 2-3 minute dissolution period.

Optional but recommended:

• Permanent marker. To write the reconstitution date and concentration on the vial label.
• Vial adapter or needle with venting. Prevents vacuum buildup when withdrawing liquid. Not required but makes the process smoother.

Do not reconstitute if the powder has changed color (tirzepatide powder is white to off-white), if the vial is cracked, or if the rubber stopper is loose or damaged.

The concentration decision: choosing your bacteriostatic water volume

The volume of bacteriostatic water you add determines the concentration, which determines every future dose measurement. Four common options for a 60 mg vial:

Bacteriostatic water added	Final concentration	2.5 mg dose	5 mg dose	10 mg dose	15 mg dose	Total vial volume
2 mL	30 mg/mL	8.3 units	16.7 units	33.3 units	50 units	2 mL
3 mL	20 mg/mL	12.5 units	25 units	50 units	75 units	3 mL
4 mL	15 mg/mL	16.7 units	33.3 units	66.7 units	100 units	4 mL
6 mL	10 mg/mL	25 units	50 units	100 units	150 units	6 mL

How to choose:

• If you're on 2.5 mg to 7.5 mg weekly: 20 mg/mL (3 mL water) or 10 mg/mL (6 mL water). The 20 mg/mL option keeps injection volume small. The 10 mg/mL option gives whole-number units for 2.5 mg and 5 mg doses.
• If you're on 10 mg to 15 mg weekly: 20 mg/mL (3 mL water). Doses land on clean half-unit or whole-unit markings, and injection volume stays under 1 mL.
• If injection volume is a concern: 20 mg/mL or 30 mg/mL. Higher concentrations mean smaller injection volumes but harder-to-read unit counts.
• If you want the simplest math: 10 mg/mL (6 mL water). Every milligram of tirzepatide equals 10 units on the syringe.

Your pharmacy's instructions may specify a volume. If they don't, or if the instructions create fractional-unit dosing you find hard to read, 3 mL is the default recommendation for 60 mg vials.

The concentration you choose is permanent for that vial. You can't add more water later to dilute it (the vial is sealed after first puncture and adding liquid risks contamination). Choose before reconstituting.

Step-by-step reconstitution protocol

This protocol assumes you're creating a 20 mg/mL solution (3 mL bacteriostatic water into a 60 mg vial). Adjust water volume for other concentrations.

Preparation (2 minutes):

1. Wash your hands with soap and water for 20 seconds. Dry with a clean towel.
2. Set up your work surface. Wipe with disinfectant. Lay out all materials within arm's reach.
3. Inspect both vials. Tirzepatide powder should be white to off-white, loose or as a cake at the bottom of the vial. Bacteriostatic water should be clear and colorless. Check expiration dates on both.
4. Remove plastic caps from both vials. Don't touch the rubber stoppers with your fingers.
5. Wipe both rubber stoppers with separate alcohol swabs. Let them air-dry for 10 seconds.

Drawing bacteriostatic water (1 minute):

1. Attach a needle to a 3 mL syringe. Keep the cap on the needle until ready to insert.
2. Pull the syringe plunger back to draw 3 mL of air into the barrel.
3. Remove the needle cap. Insert the needle into the bacteriostatic water vial through the center of the rubber stopper.
4. Push the 3 mL of air into the vial. This prevents vacuum formation when you withdraw liquid.
5. Invert the vial with the needle still inserted. Pull the plunger back to draw 3 mL of bacteriostatic water. The top edge of the black plunger seal should align with the 3 mL line.
6. Check for air bubbles. If present, tap the syringe sharply to move bubbles to the top, push them back into the vial, and re-draw to 3 mL.
7. Remove the needle from the bacteriostatic water vial. Recap the needle carefully using the one-handed scoop method (lay the cap on the table, scoop it onto the needle without using your other hand).

Reconstituting the tirzepatide vial (3-4 minutes):

1. Insert the capped needle into the tirzepatide vial. Push through the rubber stopper at a slight angle so the needle tip points toward the inside wall of the vial, not directly at the powder.
2. Inject the bacteriostatic water slowly. Aim the stream down the inside wall of the glass vial. The water should run down the wall and pool at the bottom, gently mixing with the powder. Do not spray directly onto the powder (causes foaming). The entire 3 mL injection should take 15 to 20 seconds.
3. Remove the needle. Dispose of the syringe and needle in the sharps container.
4. Swirl the vial gently. Use a circular wrist motion to mix the powder and water. Do not shake. Shaking denatures peptides and creates bubbles that take hours to dissipate.
5. Wait 2 to 3 minutes. The powder should dissolve completely. The solution will be clear and colorless to faint straw-yellow. If powder remains visible after 3 minutes, continue swirling gently. Do not use heat to speed dissolution.
6. Inspect the reconstituted solution. Hold the vial up to a light. The liquid should be clear with no visible particles, cloudiness, or undissolved powder. Small bubbles on the surface are normal and will dissipate.

Labeling and storage (1 minute):

1. Write on the vial label with a permanent marker: the date you reconstituted, the concentration (20 mg/mL), and the beyond-use date your pharmacy specifies (commonly 28 days).
2. Store in the refrigerator immediately at 36 to 46°F (2 to 8°C). Do not freeze.

Total time: 7 to 10 minutes for first reconstitution. Faster with practice.

Post-reconstitution concentration verification

After reconstitution, verify you created the concentration you intended. The math:

Concentration (mg/mL) = Total milligrams of powder ÷ Total milliliters of liquid

For a 60 mg vial with 3 mL bacteriostatic water added:

60 mg ÷ 3 mL = 20 mg/mL

The "total milliliters of liquid" is the bacteriostatic water volume you added. The powder itself adds negligible volume (less than 0.1 mL for a 60 mg vial). Some pharmacists account for powder displacement and tell patients to add slightly less water (2.9 mL instead of 3 mL), but for tirzepatide the difference is clinically irrelevant.

If you added 6 mL instead of 3 mL by mistake, your concentration is 10 mg/mL, not 20 mg/mL. Every dose you draw will be half the intended milligram amount unless you double the unit count. This is why writing the concentration on the vial immediately after reconstitution prevents errors days later when you've forgotten which volume you used.

A well-known failure mode behind "tirzepatide stopped working after I switched vials" is an unintentional concentration change between vials: the previous vial was 10 mg/mL (pharmacy-supplied pre-mixed), the new vial was self-reconstituted at 20 mg/mL, and the patient kept drawing the same unit count, effectively halving the dose. The FDA notes it has received adverse-event reports that may be related to dosing errors with compounded injectable GLP-1 products (FDA, content current as of September 1, 2026). The fix is a pre-injection checklist: confirm concentration, calculate units, cross-check against the chart.

Dose conversion chart for 60 mg vials at every common concentration

Once reconstituted, use this chart to convert your prescribed milligram dose to units on a U-100 insulin syringe. Find your concentration in the left column, then read across to your dose.

Concentration	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
10 mg/mL (6 mL water)	25 units	50 units	75 units	100 units	125 units*	150 units*
15 mg/mL (4 mL water)	16.7 units	33.3 units	50 units	66.7 units	83.3 units	100 units
20 mg/mL (3 mL water)	12.5 units	25 units	37.5 units	50 units	62.5 units	75 units
30 mg/mL (2 mL water)	8.3 units	16.7 units	25 units	33.3 units	41.7 units	50 units

*Doses above 100 units require a 1 mL syringe or splitting into two injections. Most 0.5 mL and 0.3 mL insulin syringes max out at 50 or 30 units.

Quick conversion formula:

Units = (Dose in mg ÷ Concentration in mg/mL) × 100

Example: 7.5 mg dose at 20 mg/mL = (7.5 ÷ 20) × 100 = 37.5 units

For fractional units (8.3, 12.5, 16.7), use a syringe with half-unit markings. Most 0.3 mL U-100 syringes have these. If your syringe only has whole-unit markings, round to the nearest unit or choose a different concentration.

The three failure modes of compounded reconstitution

Three failure modes account for most reconstitution problems:

Failure Mode 1: Powder doesn't fully dissolve.

Cause: Water injected too quickly, directly onto the powder, creating a clump that won't dissolve. Or water is too cold (straight from refrigerator).

Prevention: Let bacteriostatic water sit at room temperature for 10 minutes before reconstituting. Inject slowly down the vial wall. If clumping occurs, let the vial sit at room temperature (not above 77°F) for 10 to 15 minutes, then swirl again. Do not microwave, do not use hot water.

Failure Mode 2: Solution is cloudy or has particles immediately after reconstitution.

Cause: Contaminated bacteriostatic water, expired powder, or peptide aggregation from shaking.

Prevention: Check expiration dates before starting. Never shake. If cloudiness appears despite proper technique, the vial is unusable. Contact the pharmacy for a replacement. Do not inject cloudy tirzepatide.

Failure Mode 3: Dose calculations don't match the expected number of doses in the vial.

Cause: Wrong concentration created (added incorrect water volume) or math error in unit conversion.

Prevention: Before first dose, calculate total doses available: 60 mg total ÷ your weekly dose in mg = number of weeks the vial should last. A 60 mg vial should provide 6 weeks at 10 mg/week, 4 weeks at 15 mg/week, 24 weeks at 2.5 mg/week. If you run out early or have excess, recheck your concentration and unit conversion.

A decision tree for troubleshooting:

• Powder won't dissolve after 5 minutes of swirling → Let vial sit at room temperature for 10 minutes → Swirl again → Still not dissolved after 20 minutes total → Contact pharmacy, do not use.
• Solution is clear but faint yellow instead of colorless → Normal if your compounding pharmacy adds B12 → Check vial label for "cyanocobalamin" or "vitamin B12" → If not listed, call pharmacy.
• Solution is cloudy or has floating particles → Do not use → Contact pharmacy for replacement → Store unusable vial in refrigerator in case pharmacy requests return for analysis.
• You added the wrong volume of bacteriostatic water → Calculate actual concentration created → Adjust all future dose unit counts using the conversion formula → Write corrected concentration on vial label → Consider reconstituting a new vial correctly to avoid ongoing confusion.

Storage, stability, and visual inspection requirements

Before reconstitution: Store lyophilized powder as the vial label and pharmacy instructions direct, and use it by the printed date. There is no published stability standard for compounded tirzepatide powder, and an earlier version's 6-to-12-month range has been removed. Store in the original packaging away from light.

After reconstitution: Refrigerate at 36 to 46°F immediately. Discard by the beyond-use date your pharmacy gives, commonly 28 days under the USP <797> multiple-dose convention; some pharmacies specify 21 days. This is a sterility convention, not a measured stability result. Use the more conservative date if uncertain.

Freezing: Do not freeze reconstituted tirzepatide. Freezing causes peptide aggregation. If a vial accidentally freezes (left in the back of a refrigerator set too cold), discard it. Thawed tirzepatide is not safe to use even if it looks clear.

Travel: Use an insulated medication travel case with a gel ice pack (not direct ice). TSA allows syringes and medication vials in carry-on with a prescription label or doctor's note. For comparison, the approved solution may sit at room temperature up to 86°F for a total of 21 days (single-dose) or 30 days (multi-dose) per the Zepbound label; no such data exist for a vial you reconstituted, so minimize time outside refrigeration and follow the pharmacy's instructions.

Visual inspection before every injection:

Inspect the vial each time you draw a dose. You're looking for:

• Clarity: Should remain clear, not cloudy or hazy.
• Color: Colorless to faint straw-yellow. Pink or red tint indicates added B12 (check label). Dark amber, brown, or orange is abnormal.
• Particles: No visible particles, fibers, or floating material. Small air bubbles are fine.
• Consistency: Liquid, not gel-like or syrupy.

If any of these change between injections, stop using the vial. Peptide aggregation can occur even under proper refrigeration, especially if the vial experienced temperature fluctuations (door left open, power outage, transported without cooling).

Correction, September 2026: an earlier version cited a 2023 Journal of Pharmaceutical Sciences study (Maggio et al.) reporting 3.1 percent aggregation in compounded samples versus 0.2 percent in brand pens. That study could not be found in PubMed and has been removed from this page and its sources. The practical rule is unchanged: inspect before every injection.

When reconstituted tirzepatide fails the safety check

Do not inject reconstituted tirzepatide if:

• The solution is cloudy, discolored (other than faint yellow from B12), or contains particles. Cloudiness indicates aggregation or contamination. Particles can be glass shards (from vial damage), rubber fragments (from repeated punctures), or aggregated peptide.
• The vial has been outside refrigeration longer than your pharmacy allows. The approved solution is labeled for up to 21 or 30 days at room temperature; there is no published figure for a vial you reconstituted, so use the pharmacy's limit.
• It's past the pharmacy's beyond-use date (commonly 28 days after reconstitution). Bacterial contamination risk increases with time even if the solution looks clear.
• The vial was frozen and thawed. Freezing denatures the peptide structure. Thawed tirzepatide may look normal but has reduced or zero potency.
• You're unsure of the concentration. If you don't know how much bacteriostatic water was added, you can't calculate dose accurately. Don't guess.
• The rubber stopper is damaged or loose. Repeated or off-center punctures create channels for contamination; follow the pharmacy's guidance on how many draws a vial is meant for.

Contact your pharmacy or provider before injecting if you're uncertain. The cost of a replacement vial is lower than the risk of injecting degraded or contaminated medication.

When to use a vial despite cosmetic concerns:

• Faint yellow color with B12 listed on the label: Safe to use.
• Small air bubbles in the solution: Safe. Bubbles don't affect potency.
• Slight color variation between vials from the same pharmacy: Normal batch-to-batch variation. Safe if within the colorless-to-faint-yellow range.
• Vial label is smudged or partially illegible but you have the pharmacy's written instructions: Safe if you can verify concentration from the instructions.

FormBlends's 5-Question Pre-Injection Checklist

This checklist covers the most common reconstitution and dosing errors. Correction, September 2026: an earlier version quoted percentages for how much it reduced dosing uncertainties and pharmacy calls; those figures had no data behind them and have been removed.

Before drawing each dose, answer these five questions:

1. What is the concentration of this vial in mg/mL? (Check the vial label or your written notes. If you don't know, calculate it: total mg ÷ total mL added.)
2. What is my prescribed dose in milligrams this week? (Check your prescription or titration schedule. Dose changes during titration.)
3. How many units does that dose equal on a U-100 syringe? (Use the conversion chart or formula: (dose in mg ÷ concentration) × 100.)
4. Does the solution in the vial still look clear and colorless to faint yellow? (Hold up to light and inspect.)
5. How many days ago did I reconstitute this vial? (Check the date you wrote on the label. If more than 28 days, discard.)

If you can't answer all five confidently, stop and resolve the uncertainty before drawing the dose. The most common error pattern is patients who answer question 3 from memory ("I always draw 25 units") without re-checking concentration after switching vials.

What the approved tirzepatide vial looks like, for comparison

Nothing in the approved product requires reconstitution. The Zepbound label (September 2026) lists single-dose pens and vials of 2.5 to 15 mg in 0.5 mL, and a multi-dose vial or KwikPen holding 2.4 mL for four weekly doses of 0.6 mL at six strengths: 10, 20, 30, 40, 50 and 60 mg per 2.4 mL, which works out to 4.17, 8.33, 12.5, 16.7, 20.8 and 25 mg/mL. The 60 mg per 2.4 mL vial is the closest approved relative of the 60 mg powder vial discussed on this page, and it is a 25 mg/mL solution, a stronger concentration than any row in our reconstitution table. Storage is defined too: refrigerate at 36 to 46°F; a single-dose pen or vial may be kept at room temperature up to 86°F for a total of 21 days, a multi-dose vial or KwikPen for 30 days or four doses, and nothing frozen may be used (section 16.2). Those figures are the only published stability limits for tirzepatide of any kind, and they apply to Lilly's formulation, not to a vial you mixed yourself.

Regulatory and safety context as of September 5, 2026

Three dated facts frame the legality and risk of a 60 mg powder vial. First, the FDA declared the tirzepatide shortage resolved on December 19, 2024 (semaglutide on February 21, 2025), a decision upheld by the Fifth Circuit on August 27, 2026, so compounded copies are permitted only for a documented individual clinical need. Second, the FDA's page on unapproved GLP-1 drugs (content current as of September 1, 2026) reports more than 730 adverse-event reports for compounded tirzepatide and 990 for compounded semaglutide as of May 31, 2026, and says some may relate to dosing errors with compounded injectable products. Third, the FDA has warned sellers of tirzepatide, semaglutide, retatrutide, survodutide and mazdutide marketed "for research purposes," including a March 31, 2026 letter that specifically named tirzepatide and bacteriostatic water. A powder vial with no pharmacy label, no prescriber and no beyond-use date is an unapproved drug of unknown identity and strength, and none of the arithmetic on this page can make it safe. For what lawfully dispensed compounded tirzepatide costs, see the Compounded GLP-1 Price Index.

FAQ

How much bacteriostatic water do I add to a 60 mg tirzepatide vial?

Add 3 mL of bacteriostatic water to create a 20 mg/mL concentration, which provides clean unit measurements for all standard tirzepatide doses. You can also use 6 mL (for 10 mg/mL) if you prefer whole-number units for low doses, but injection volume doubles.

Can I use sterile water instead of bacteriostatic water?

No. Sterile water without preservative allows bacterial growth. Once you puncture the vial to draw a dose, bacteria can enter. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is why pharmacies allow a multi-dose beyond-use date (commonly 28 days). Vials reconstituted with plain sterile water are treated as single-use.

What if I added the wrong amount of water?

Calculate the actual concentration you created (60 mg ÷ mL of water added) and use that concentration for all dose conversions. Write it on the vial label. The solution is still usable, but your unit counts will differ from standard charts. If you're uncertain about the math, reconstitute a new vial correctly.

How long does reconstituted tirzepatide last?

Until the beyond-use date your pharmacy gives, commonly 28 days refrigerated at 36 to 46°F, sometimes 21. That date is a USP <797> sterility convention, not a measured stability result, because no published study has tested patient-reconstituted tirzepatide. Write the date on the vial when you reconstitute.

Can I reconstitute multiple vials at once to save time?

Yes, but only if you'll use them within their 28-day windows. Don't reconstitute more vials than you need for the next 4 weeks. Each vial's 28-day clock starts when you add water, not when you draw the first dose.

What if the powder doesn't dissolve completely?

Let the vial sit at room temperature (not above 77°F) for 10 to 15 minutes, then swirl gently again. Do not shake. Do not heat. If powder remains after 20 minutes total, the vial is defective. Contact the pharmacy for a replacement.

Why is my reconstituted tirzepatide pink or red?

Some compounding pharmacies add vitamin B12 (cyanocobalamin), which is pink-red in solution. Check your vial label for "B12" or "cyanocobalamin." If B12 isn't listed and the solution is red, call the pharmacy before using.

Can I draw my first dose immediately after reconstituting?

Yes, once the powder is fully dissolved and the solution is clear. You don't need to wait hours. Some patients prefer to refrigerate for 30 minutes to let any small bubbles dissipate, but it's not required.

How many doses are in a 60 mg vial?

Depends on your weekly dose. At 2.5 mg weekly, a 60 mg vial provides 24 doses (24 weeks). At 5 mg weekly, 12 doses. At 10 mg weekly, 6 doses. At 15 mg weekly, 4 doses. Calculate: 60 mg ÷ your dose in mg = number of doses.

What concentration should I use if I'm on a high dose like 12.5 mg or 15 mg?

Use 20 mg/mL (3 mL bacteriostatic water). This keeps injection volume manageable (62.5 units for 12.5 mg, 75 units for 15 mg). At 10 mg/mL you'd need to inject 125 to 150 units, which exceeds the capacity of most insulin syringes.

Can I use the same needle to draw bacteriostatic water and inject it into the tirzepatide vial?

Yes, but using a fresh needle for the tirzepatide vial reduces the risk of introducing contaminants. Needles are inexpensive. If you reuse the same needle, don't let it touch any non-sterile surface between steps.

What if I accidentally shake the vial instead of swirling?

Let it sit undisturbed for 30 minutes. Bubbles will rise to the top. Shaking can denature some peptide molecules, but a brief shake (1-2 seconds) usually doesn't ruin the entire vial. Avoid shaking in the future.

Do I need to refrigerate bacteriostatic water before or after opening?

Unopened bacteriostatic water is stable at room temperature. After opening, refrigeration extends shelf life but isn't required if you'll use it within a few weeks. Check the manufacturer's label. Once you've used it to reconstitute tirzepatide, the tirzepatide vial must be refrigerated.

Can I travel with a reconstituted vial?

Yes. Use an insulated case with a gel ice pack. There is no published room-temperature limit for a vial you reconstituted, so keep it cold and follow the pharmacy's instructions. TSA allows medication vials and syringes in carry-on luggage with a prescription label.

What's the difference between reconstituting 60 mg versus 30 mg vials?

Only the total milligrams of powder. The reconstitution process is identical. For a 30 mg vial, add 1.5 mL of bacteriostatic water to create 20 mg/mL (half the water because half the powder). The concentration options and technique are the same.

Is a 60 mg tirzepatide powder vial FDA approved?

No. FDA-approved tirzepatide (Zepbound and Mounjaro) is supplied only as a solution; the approved 60 mg multi-dose vial holds 2.4 mL at 25 mg/mL and is never reconstituted (Zepbound label, September 2026). Powder vials are either compounded under a prescription, which is lawful only for a documented individual need now that the shortage ended on December 19, 2024, or sold as unapproved research chemicals, which the FDA has warned against.

How long can the approved tirzepatide vial stay at room temperature?

The Zepbound label (section 16.2, September 2026) allows a single-dose pen or vial up to 21 days total at room temperature up to 86°F (30°C), and a multi-dose vial or KwikPen 30 days, 30 days after first use, or four weekly doses, whichever comes first. Anything frozen must be discarded. No comparable figure exists for a compounded or self-reconstituted vial, so follow your pharmacy's beyond-use date instead.

Does the FDA track problems with compounded tirzepatide?

Yes. As of May 31, 2026 the FDA had received more than 730 adverse-event reports for compounded tirzepatide and 990 for compounded semaglutide, some of which it says may be related to dosing errors with compounded injectable products (FDA, content current as of September 1, 2026). These are voluntary MedWatch reports, not incidence rates. You can report a problem with any compounded product to MedWatch yourself.

Related guides

• How to Reconstitute Tirzepatide: A Step-by-Step Guide for Safe Mixing and Storage
• How to Reconstitute Tirzepatide at Home: A Step-by-Step Guide for Safe and Accurate Mixing
• How to Reconstitute a 30 mg Vial of Tirzepatide: Step-by-Step Protocol for Safe Mixing
• How to Reconstitute 5mg Semaglutide: A Step-by-Step Guide for Safe Preparation
• How to Reconstitute Tirzepatide 10mg: The Complete Mixing Protocol for Lyophilized Peptide Vials
• How to Reconstitute Tirzepatide 30mg: The Complete Mixing Protocol for Compounded Peptides
• Tool: reconstitution calculator

Sources

1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515.
2. United States Pharmacopeia. Chapter 797: Pharmaceutical compounding - sterile preparations. USP 44-NF 39. 2021.
3. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021;46:101102.
4. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021;44(7):1604-1612.
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
6. DailyMed (NIH). Zepbound (tirzepatide) prescribing information: sections 3 (strengths), 16.2 (storage) and vial instructions for use. Published September 2, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
7. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (adverse-event counts as of May 31, 2026; research-use warning letters). Content current as of September 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
8. U.S. Food and Drug Administration. Warning letter to Gram Peptides: retatrutide, tirzepatide and bacteriostatic water marketed as research use only. March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
9. U.S. Food and Drug Administration. Tirzepatide shortage resolution notice, December 19, 2024. https://www.fda.gov/media/185577/download
10. FormBlends. Compounded GLP-1 Price Index data feed. As of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.